Literature DB >> 9466547

New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4.

D R Martin1, S J Walker, M G Baker, D R Lennon.   

Abstract

New Zealand is experiencing an epidemic of serogroup B meningococcal disease, which has taken the rate of disease from an average of 1.5/100,000 population in the preepidemic years of 1989 and 1990 to 14.0/100,000 in 1996. Sterile-site isolates of Neisseria meningitidis from cases of invasive disease have been phenotypically characterized by serogrouping, serotyping, and serosubtyping, revealing the involvement of a strain with phenotype B:4:P1.4. Macrorestriction analysis using pulsed-field gel electrophoresis on 667 meningococci isolated from cases during the epidemic has identified the clonal relationship of meningococci expressing the PorA P1.4 antigen. Multilocus enzyme electrophoresis has shown the epidemic strain B:4:P1.4 to belong to lineage III. The recorded characteristics of New Zealand's epidemic are consistent with previous serogroup B epidemics in other parts of the world.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9466547     DOI: 10.1086/517385

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  36 in total

1.  NmeSI restriction-modification system identified by representational difference analysis of a hypervirulent Neisseria meningitidis strain.

Authors:  A Bart; Y Pannekoek; J Dankert; A van der Ende
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

2.  Evaluation of porB PCR-amplicon restriction endonuclease analysis as a method to determine porB variable-region sequences in nonserotypeable meningococci.

Authors:  Kristin H Dyet; Robin S Simmonds; Diana R Martin
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

3.  Multilocus restriction typing method to predict the sequence type of meningococci.

Authors:  Kristin H Dyet; Robin S Simmonds; Diana R Martin
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

Review 4.  Bacterial outer membrane vesicles in disease and preventive medicine.

Authors:  Can M Unal; Viveka Schaar; Kristian Riesbeck
Journal:  Semin Immunopathol       Date:  2010-12-12       Impact factor: 9.623

5.  Inhibition of the alternative pathway of nonhuman infant complement by porin B2 contributes to virulence of Neisseria meningitidis in the infant rat model.

Authors:  Lisa A Lewis; David M Vu; Dan M Granoff; Sanjay Ram
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

6.  Sequence variation in the porB gene from B:P1.4 meningococci causing New Zealand's epidemic.

Authors:  Kristin H Dyet; Diana R Martin
Journal:  J Clin Microbiol       Date:  2005-02       Impact factor: 5.948

7.  Combined administration of meningococcal serogroup B outer membrane vesicle vaccine and conjugated serogroup C vaccine indicated for prevention of meningococcal disease is safe and immunogenic.

Authors:  Ingeborg S Aaberge; Philipp Oster; Oddveig S Helland; Anne-Cathrine Kristoffersen; Ellen Ypma; E Arne Høiby; Berit Feiring; Hanne Nøkleby
Journal:  Clin Diagn Lab Immunol       Date:  2005-05

8.  Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine.

Authors:  Ray Borrow; Ingeborg S Aaberge; George F Santos; T Lynn Eudey; Philipp Oster; Anne Glennie; Jamie Findlow; E Arne Høiby; Einar Rosenqvist; Paul Balmer; Diana Martin
Journal:  Clin Diagn Lab Immunol       Date:  2005-08

9.  Rapid genetic grouping of factor h-binding protein (genome-derived neisserial antigen 1870), a promising group B meningococcal vaccine candidate.

Authors:  Peter T Beernink; Arunas Leipus; Dan M Granoff
Journal:  Clin Vaccine Immunol       Date:  2006-07

10.  Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine.

Authors:  Berit Feiring; Jan Fuglesang; Philipp Oster; Lisbeth M Naess; Oddveig S Helland; Sandrine Tilman; Einar Rosenqvist; Marianne A R Bergsaker; Hanne Nøkleby; Ingeborg S Aaberge
Journal:  Clin Vaccine Immunol       Date:  2006-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.